Insider Selling: Momenta Pharmaceuticals VP Unloads 27,159 Shares of Stock (MNTA)
Momenta Pharmaceuticals (NASDAQ:MNTA) VP John Bishop sold 27,159 shares of the company’s stock on the open market in a transaction that occurred on Thursday, January 9th. The shares were sold at an average price of $19.50, for a total value of $529,600.50. Following the completion of the sale, the vice president now directly owns 93,780 shares in the company, valued at approximately $1,828,710. The transaction was disclosed in a filing with the SEC, which is available at this link.
Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) traded up 0.72% during mid-day trading on Friday, hitting $19.70. The stock had a trading volume of 390,720 shares. Momenta Pharmaceuticals has a 52-week low of $11.22 and a 52-week high of $19.90. The stock has a 50-day moving average of $17.82 and a 200-day moving average of $16.11. The company’s market cap is $1.008 billion.
Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.02. The company had revenue of $10.80 million for the quarter, compared to the consensus estimate of $8.60 million. During the same quarter in the previous year, the company posted ($0.51) earnings per share. The company’s revenue for the quarter was up 111.8% on a year-over-year basis. On average, analysts predict that Momenta Pharmaceuticals will post $-1.99 earnings per share for the current fiscal year.
A number of research firms have recently commented on MNTA. Analysts at Sanford C. Bernstein raised their price target on shares of Momenta Pharmaceuticals from $20.00 to $24.00 in a research note to investors on Tuesday, November 5th. They now have an “outperform” rating on the stock. Separately, analysts at TheStreet upgraded shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note to investors on Sunday, November 3rd. Finally, analysts at TheStreet upgraded shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note to investors on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Momenta Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $18.83.
Momenta Pharmaceuticals, Inc (NASDAQ:MNTA) is a biotechnology company specializing in the characterization and process engineering of complex molecules.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.